| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.novartis.in | |
| Market Cap | 2,565.74 Cr. | |
| Enterprise Value(EV) | 2,075.67 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 38.69 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 26.86 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 42.21 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 295.19 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 3.52 | Calculated using Price: 1,039.15 |
| Dividend Yield | 4.57 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.47 Cr. | 24,690,797 Shares |
| FaceValue | 5 | |
| About Novartis India Ltd. | ||
| Novartis has been in India since 1947. The Group operates in India through four entities namely Novartis India Limited, listed on the Mumbai Stock Exchange, Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron-Behring Vaccine Private Limited. In India Novartis have a presence in pharmaceuticals, generics (pharmaceutical products that are off patent), Vaccines, OTC (over-the-counter medicines), eyecare and Animal Health. | ||
| 1 Day |
|
+0.40% |
| 1 Week |
|
+1.43% |
| 1 Month |
|
+1.03% |
| 3 Month |
|
+3.78% |
| 6 Month |
|
+54.64% |
| 1 Year |
|
+74.62% |
| 2 Year |
|
+65.31% |
| 5 Year |
|
+50.25% |
| 10 Year |
|
+118.72% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 8.06 | 18.01 | 5.38 | 9.4 | 6.89 | 1.36 | 2.91 | -0.53 | 14.07 | |
| Return on Capital Employed (%) | 9.52 | 24.77 | 8.75 | 19.72 | 11.7 | 4.73 | 6.67 | 0.14 | 15.96 | |
| Return on Assets (%) | 3.89 | 11.38 | 3.27 | 3.75 | 2.51 | 0.62 | 1.22 | -0.18 | 5.09 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1,002 | 1,194 | 920 | 734 | 759 | 721 | 711 | 692 | 776 | 702 | |
| Non Curr. Liab. | 697 | 26 | 828 | 898 | 891 | 99 | 1,131 | 984 | 1,008 | 14 | |
| Curr. Liab. | 362 | 204 | 323 | 482 | 367 | 417 | 357 | 334 | 268 | 139 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 2,060 | 1,425 | 2,070 | 2,113 | 2,018 | 1,237 | 2,199 | 2,010 | 2,052 | 855 | |
| Non Curr. Assets | 846 | 161 | 959 | 1,009 | 1,029 | 240 | 1,277 | 1,183 | 1,266 | 259 | |
| Curr. Assets | 1,215 | 1,264 | 1,111 | 1,104 | 989 | 997 | 922 | 826 | 786 | 597 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 2,060 | 1,425 | 2,070 | 2,113 | 2,018 | 1,237 | 2,199 | 2,010 | 2,052 | 855 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 873 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 330 | |
| Other Income | 112 | 245 | 72 | 174 | 78 | 36 | 34 | 34 | 58 | 68 | |
| Total Income | 985 | 934 | 728 | 738 | 569 | 475 | 416 | 433 | 437 | 398 | |
| Total Expenditure | -881 | -659 | -632 | -572 | -479 | -427 | -356 | -373 | -314 | -267 | |
| PBIDT | 104 | 275 | 96 | 166 | 91 | 48 | 60 | 60 | 123 | 131 | |
| Interest | 0 | 0 | -1 | -6 | -2 | -6 | -8 | -5 | -2 | -2 | |
| Depreciation | -4 | -3 | -4 | -3 | -3 | -13 | -12 | -10 | -6 | -5 | |
| Taxation | -14 | -73 | -35 | -79 | -34 | -19 | -19 | 0 | -12 | -29 | |
| Exceptional Items | -6 | -50 | |||||||||
| PAT | 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 96 | |
| Adjusted EPS | 25 | 62 | 20 | 32 | 21 | 4 | 8 | -2 | 42 | 39 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -5 | -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | |
| Cash Fr. Inv. | 22 | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | |
| Cash Fr. Finan. | -38 | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | |
| Net Change | -20 | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | |
| Cash & Cash Eqvt | 15 | 637 | 25 | 76 | 38 | 88 | 79 | 68 | 158 | 19 |
|
Thu, 25 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
|||||||||||||||||||||
|
Thu, 25 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Nikhil Malpani Designation: Company Secretary and Compliance Officer EmailId: india.investors@novartis.com Name of the Chief Financial Officer: Shilpa Joshi Designation: Whole Time Director and Chief Financial Officer EmailId: india.invetors@novartis.com Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Sat, 20 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
| Thu, 02 May 2024 |
High Increase in 6 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
Close Crossing Last Month Close From Below
|
Closing Near 20 SMA
|
